Carbonic Anhydrase

Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Related Products (265)
Recombinant Proteins (31)
Carbonic Anhydrase Isoform Comparison

By Effects:	Inhibitors (246) Activators (2) Modulators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-13650

Indisulam	Inhibitor	99.80%
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.

HY-B0782

Acetazolamide	Inhibitor	99.89%
Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.

HY-13513

U-104	Inhibitor	99.95%
U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with K_i values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model.

HY-Y0271

Urea		≥98.0%
Urea is a powerful protein denaturant via both direct and indirect mechanisms. A potent emollient and keratolytic agent. Used as a diuretic agent. Blood urea nitrogen (BUN) has been utilized to evaluate renal function. Widely used in fertilizers as a source of nitrogen and is an important raw material for the chemical industry.

HY-B1480

Ethoxzolamide	Inhibitor	99.85%
Ethoxzolamide is a carbonic anhydrase inhibitor with K_i of 1 nM.

HY-P10761

DPI-4452	Modulator	98.27%
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models. DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-402723

hCAVII/IX-IN-1	Inhibitor
hCAVII/IX-IN-1 (compound 4) is a hCAVII/IX inhibitor, with Ki values of 56.5 nM and 38.2 nM, respectively. hCAVII/IX-IN-1 can be used in anticancer research.

HY-W012168

4-Chloro-3-sulfamoylbenzoic acid	Inhibitor	99.79%
4-Chloro-3-sulfamoylbenzoic acid is an inhibitor of human carbonic anhydrase, targeting the cytosolic isoforms hCA I and hCA II (glaucoma-associated), and the transmembrane isoforms hCA IV and hCA IX (tumor hypoxia-induced).

HY-B0122

Topiramate	Inhibitor	≥98.0%
Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.

HY-N0639

Punicalin	Inhibitor	99.88%
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.

HY-P99023

Girentuximab	Inhibitor	99.90%
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

HY-B0553

Methazolamide	Inhibitor	99.41%
Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a K_i of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage.

HY-B0124

Zonisamide	Inhibitor	99.85%
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.

HY-B0283

Acipimox	Inhibitor	99.86%
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.

HY-B0782A

Acetazolamide sodium	Inhibitor	99.54%
Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.

HY-B0109A

Dorzolamide hydrochloride	Inhibitor	99.86%
Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC₅₀ values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.

HY-B0588

Brinzolamide	Inhibitor	99.91%
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.

HY-B1424

Benzthiazide	Inhibitor	99.70%
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with K_is of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells.

HY-110243

CAIX Inhibitor S4	Inhibitor	99.04%
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a K_i of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (K_i=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth.

HY-P1775

Carbonic anhydrase, Bovine erythrocytes
Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.

Acetazolamide				CA IX		99.89%
U-104				CA IX	CA XII	99.95%
DPI-4452				hCA IX, Kd: 0.25 nM		98.27%
hCAVII/IX-IN-1				hCA IX, Ki: 38.2 nM
Girentuximab				CA IX		99.90%
Methazolamide			CA Ⅱ			99.41%
Zonisamide			CA Ⅱ			99.85%
Acetazolamide sodium				CA IX		99.54%
Dorzolamide hydrochloride			CA Ⅱ			99.86%
Brinzolamide			CA Ⅱ			99.91%
CAIX Inhibitor S4				CA IX		99.04%
Benzolamide			CA Ⅱ			99.07%
Furagin				hCA IX, Ki: 260 nM	hCA XII, Ki: 57 nM	99.84%
Acetazolamide (Standard)				CA IX		99.69%
2-Aminobenzenesulfonamide				CA IX		99.90%
Halazone			CA Ⅱ
Benzenesulphonamide			CA Ⅱ			99.51%
Fluorometholone acetate			CA Ⅱ			98.54%
Carbonic anhydrase inhibitor 2			CA Ⅱ			98.40%
hCAIX-IN-18		hCA I, IC₅₀: 3.5 nM	hCA II, IC₅₀: 9.4 nM	hCA IX, IC₅₀: 43 nM	hCA XII, IC₅₀: 8.2 nM	98.52%
Procodazole				CA IX, IC₅₀: 8.35 μM		99.73%
EMAC10101d			CA Ⅱ			99.77%
Enpp/Carbonic anhydrase-IN-1			CA Ⅱ, IC₅₀: 0.88 μM	CA IX, IC₅₀: 1.02 μM		99.57%
hCAII-IN-8			hCA II, IC₅₀: 0.18 μM			99.41%
hCAXII-IN-9		hCA I, Ki: 7192.6 nM	hCA II, Ki: 188.6 nM	hCA IX, Ki: >100000 nM	hCA XII, Ki: 28 nM
Lasamide				hCA IX, Ki: 2.67 nM	hCA XII, Ki: 7.54 nM	99.97%
hCAIX/XII-IN-5				hCA IX, Ki: 93.9 nM	hCA XII, Ki: 85.7 nM
α-Glucosidase-IN-63			hCA II, Ki: 7.0 nM	hCA IX, Ki: 64.1 nM	hCA XII, Ki: 19.9 nM
hCAIX/XII-IN-6			hCA II, Ki: 2950 nM	hCA IX, Ki: 4.1 nM	hCA XII, Ki: 7.7 nM
hCAIX-IN-6					CA XII
BChE-IN-36	hCA VB, KA: 893 nM	hCA I, KA: 266 nM	hCA II, KA: 76.9 nM
hCAII-IN-9			hCA II, IC₅₀: 1.18 μM	hCA IX, IC₅₀: 0.17 μM	hCA XII, IC₅₀: 2.99 μM
β-Glucuronidase/hCAII-IN-2			hCA II, IC₅₀: 21.77 μM
β-Glucuronidase/hCAII-IN-1			hCA II, IC₅₀: 4.91 μM
hCAXII-IN-1				CA IX
hCAIX/XII-IN-11				hCA IX, Ki: 0.7 μM	hCA XII, Ki: 0.7 μM
Carbonic anhydrase inhibitor 14		hCA I, Ki: 1203 nM	hCA II, Ki: 99.7 nM	hCA IX, Ki: 9.4 nM	hCA XII, Ki: 27.7 nM
Carbonic anhydrase inhibitor 3			CA Ⅱ
CA Ⅱ-IN-1			hCA II, : 0.44 μM
CAIX/CAXII-IN-1			CA Ⅱ	CA IX	CA XII
Brinzolamide hydrochloride			hCA II, IC₅₀: 3.2 nM
hCAIX-IN-24				hCA IX, Ki: 32.1 nM	hCA XII, Ki: 8.1 nM
hCAIX-IN-19				hCA IX, Ki: 6.2 nM
AChE/hCA I-IN-1		hCA I, IC₅₀: 283.3 nM	hCA II, IC₅₀: 265.9 nM
hCAIX-IN-17			CA Ⅱ	CA IX	CA XII
Carbonic anhydrase/AChE-IN-1		hCA I, Ki: 24.42 nM	hCA II, Ki: 19.95 nM
hCAIX-IN-14				hCA IX, Ki: 134.8 nM
Carbonic anhydrase inhibitor 10				CA IX
hCA/VEGFR-2-IN-5				hCA IX, IC₅₀: 40 nM	hCA XII, IC₅₀: 3.2 nM
COX-2-IN-30		hCA I, Ki: 183.4 nM	hCA II, Ki: 81.4 nM	hCA IX, Ki: 38.4 nM	hCA XII, Ki: 21.6 nM
hCAI/II-IN-10		hCA I, IC₅₀: 4.32 nM	hCA II, IC₅₀: 3.89 nM
hCAII-IN-5			hCA II, IC₅₀: 4.55 μM
hCAIX-IN-22					hCA XII, Ki: 9.7 nM
hCAII-IN-6			CA Ⅱ
AChE/CA I-IN-1		hCA I, Ki: 0.53 μM
Enpp/Carbonic anhydrase-IN-2				CA IX, IC₅₀: 0.33 μM	CA XII, IC₅₀: 0.68 μM	99.76%
CA IX-IN-2			CA Ⅱ, IC₅₀: 430 nM	CA IX, IC₅₀: 5.6 nM	CA XII, IC₅₀: 7.4 nM
hCA I-IN-4		hCA I, Ki: 29.94 nM	hCA II, Ki: 17.72 nM
hCAII/IX-IN-1			hCA II, Ki: 7.4 nM	hCA IX, Ki: 7 nM
DTP348				CA IX, Ki: 8.3 nM
Carbonic anhydrase inhibitor 33		hCA I, Ki: 663 nM	hCA II, Ki: 76.1 nM	hCA IX, Ki: 19.7 nM	hCA XII, Ki: 26.1 nM
HCAIX-IN-2		CA I, Ki: 2481 nM	hCA II, Ki: 456.2 nM	hCA IX, Ki: 24.6 nM	hCA XII, Ki: 45.3 nM
hA2A/hCA XII modulator 1			CA Ⅱ		CA XII
hCA I-IN-3		hCA I, IC₅₀: 4.77 nM	hCA II, IC₅₀: 9.66 nM
hCAII/XII-IN-1			CA Ⅱ, Ki: 9.4 nM		hCA XII, Ki: 8.4 nM
VM4-037				CA IX
GZ22-4			CA Ⅱ, Kd: 200 nM	CA IX, Kd: 0.2 nM	CA XII, Kd: 80 nM
DPP IV/hCA II-IN-1		CA I, Ki: 0.2615 μM	CA Ⅱ, IC₅₀: 36.1 nM hCA II, Ki: 0.0361 μM	hCA IX, Ki: 0.1328
CAII-IN-3			bovine CA-II, IC₅₀: 13.4 μM
Carbonic anhydrase inhibitor 12			CA Ⅱ
hCAII-IN-10		hCA I, IC₅₀: 29.2 μM	hCA II, IC₅₀: 14 nM
hCAII-IN-4			hCA II, IC₅₀: 7.78 μM
Carbonic anhydrase inhibitor 9			CA Ⅱ	CA IX
hCAIX-IN-15				hCA IX, Ki: 38.8 nM
CAIX/CAXII-IN-2				hCA IX, Ki: 8.9 nM	hCA XII, Ki: 5.3 nM
CA IX/VEGFR-2-IN-2				CA IX, Ki: 3.1 μM
hCAIX/XII-IN-8		hCA I, Ki: 5269 nM	hCA II, Ki: 72.0 nM	hCA IX, Ki: 8.5 nM	hCA XII, Ki: 6.7 nM
hCAIX-IN-21		hCA I, Ki: 13600 nM	hCA II, Ki: 3.5 nM	hCA IX, Ki: 5.2 nM	hCA XII, Ki: 12.6 nM
Methazolamide-d₆			CA Ⅱ
CA IX/VEGFR-2-IN-3			CA Ⅱ, IC₅₀: 41 nM
hCAIX-IN-10				CA IX
hCAII-IN-3			CA Ⅱ	CA IX	CA XII
hCAI/II-IN-8		hCA I, IC₅₀: 21.35 nM	hCA II, IC₅₀: 7.12 nM
hCAIX-IN-23				hCA IX, Ki: 10.4 nM	hCA XII, Ki: 8.5 nM
hCAIX/XII-IN-15		hCA I, Ki: >100 μM	hCA II, Ki: >100 μM	hCA IX, Ki: 0.42 μM	hCA XII, Ki: 4.37 μM
CA/MAO-B-IN-1	hCA VB, IC₅₀: 8.8 nM hCA VA, IC₅₀: 9.6 nM	hCA I, IC₅₀: 553.1 nM	hCA II, IC₅₀: 41.1 nM		hCA XII, IC₅₀: 196 nM	98.34%
hCAIX/XII-IN-9		hCA I, Ki: 1658 nM	hCA II, Ki: 184.8 nM	hCA IX, Ki: 8.9 nM	hCA XII, Ki: 64.8 nM
ALP/Carbonic anhydrase-IN-1			CA Ⅱ, IC₅₀: 0.44 μM	CA IX, IC₅₀: 1.61 μM	CA XII, IC₅₀: 0.51 μM	99.90%
HCAIX-IN-1		hCA I, Ki: 694.9 nM	hCA II, Ki: 126.6 nM	hCA IX, Ki: 3.3 nM	hCA XII, Ki: 9.8 nM
Dorzolamide (hydrochloride) (Standard)			CA Ⅱ
Acetazolamide-¹³C₂,d₃				CA IX
Carbonic anhydrase inhibitor 20		hCA I, Ki: 47.6 nM ([1])	hCA II, Ki: 36.5 nM ([1])	hCA IX, Ki: 8.3 nM ([1])	hCA XII, Ki: 2.7 nM ([1])
hCAIX-IN-12				CA IX
hCAIX/XII-IN-1				CA IX
hCAIX/XII-IN-7		hCA I, Ki: 503.7 nM	hCA II, Ki: 59 nM	hCA IX, Ki: 3.2 nM	hCA XII, Ki: 9.2 nM
CAIX/CAXII-IN-4			CA Ⅱ, Ki: 3.035 μM	CA IX, Ki: 1.324 μM	CA XII, Ki: 0.435 μM
Phenylsulfamide			hCA II, Kd: 45.50 μM hCA II, Ki: 79.60 μM
hCAIX-IN-8				CA IX
Dorzolamide-d₅			CA Ⅱ
L-662583			hCA II, IC₅₀: 0.7 nM
CA IX-IN-3				CA IX, IC₅₀: 0.48 nM
Carbonic anhydrase inhibitor 25		hCA I	hCA II
hCAI/II-IN-7	bovine CA, Ki: 20.57 μM	hCA I, Ki: 23 nM	hCA II, Ki: 44 nM
hCAIX/XII-IN-14			hCA II, Ki: 9.4 nM	hCA IX, Ki: 5.6 nM	hCA XII, Ki: 6.3 nM
Carbonic anhydrase inhibitor 19		hCA I, IC₅₀: 49.1 nM	hCA II, IC₅₀: 9.4 nM	hCA IX, IC₅₀: 4.7 nM	hCA XII, IC₅₀: 6.7 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Carbonic Anhydrase

Carbonic Anhydrase

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Related Products (265)

Recombinant Proteins (31)

Carbonic Anhydrase Isoform Comparison

Carbonic Anhydrase Related Products (265):